Who was studied?
66 enrolled patients as of 31 October 2024.
What does the publication report?
In 66 patients, ORR was 22.7% (15/66), DCR 56.1% (37/66), median PFS 4.3 months, and median OS 10.3 months.
Safety findings
TRAEs occurred in 57/66 (86.4%) patients; 6/66 (9.1%) had grade ≥3 events.
How should we interpret it?
Conference abstract with limited methodological detail and no randomized comparator; linked to the same PRaG 2.0 study, not a separate trial.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial. · DOI: 10.1200/JCO.2025.43.16_suppl.2616
Related publications from the same research program
- PRaG 2.0: the 2023 ASTRO conference report
- PRaG 2.0: the 2023 ASCO interim report
- A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors.
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.